# Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

> **NCT05972135** · PHASE2 · RECRUITING · sponsor: **SCRI Development Innovations, LLC** · enrollment: 100 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Teclistamab
- **DRUG:** Talquetamab
- **DRUG:** Tocilizumab
- **DRUG:** Oral Dexamethasone

## Key facts

- **NCT ID:** NCT05972135
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-23
- **Primary completion:** 2027-08
- **Final completion:** 2027-10
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05972135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05972135, "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05972135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*